Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

All patients had received at least 2 prior lines of systemic cancer ... assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities.

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

Two international academic journals have found that it is effective to apply classical treatments to patients with advanced liver cancer who are not effective even in the latest immune anticancer ...

Research showed that nearly two-thirds of patients sustained clinically meaningful relief over 4 years after a 60-day PNS treatment for chronic low back pain.

The downregulation of ADH4 expression induces hepatocyte apoptosis, thereby contributing to liver fibrosis and the initiation of hepatocellular carcinoma (HCC). Moreover, sustained suppression of ...

Future Oncol. 2013;9(10):1533-1548. The dual targeting of VEGF and EGFR was considered a logical treatment approach. Many data from Phase II studies have suggested that erlotinib may facilitate ...